AU2016319066B2 - Tissue engineering - Google Patents
Tissue engineering Download PDFInfo
- Publication number
- AU2016319066B2 AU2016319066B2 AU2016319066A AU2016319066A AU2016319066B2 AU 2016319066 B2 AU2016319066 B2 AU 2016319066B2 AU 2016319066 A AU2016319066 A AU 2016319066A AU 2016319066 A AU2016319066 A AU 2016319066A AU 2016319066 B2 AU2016319066 B2 AU 2016319066B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- scaffold
- construct
- tissue
- seeding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 287
- 210000001519 tissue Anatomy 0.000 claims abstract description 128
- 238000000034 method Methods 0.000 claims abstract description 88
- 238000010899 nucleation Methods 0.000 claims abstract description 70
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 68
- 230000004069 differentiation Effects 0.000 claims abstract description 44
- 238000002513 implantation Methods 0.000 claims abstract description 34
- 238000002347 injection Methods 0.000 claims abstract description 25
- 239000007924 injection Substances 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 210000000056 organ Anatomy 0.000 claims description 66
- 239000002609 medium Substances 0.000 claims description 56
- 238000009826 distribution Methods 0.000 claims description 44
- 230000003068 static effect Effects 0.000 claims description 42
- 238000013508 migration Methods 0.000 claims description 23
- 210000003205 muscle Anatomy 0.000 claims description 22
- 230000035755 proliferation Effects 0.000 claims description 22
- 230000005012 migration Effects 0.000 claims description 21
- 238000002054 transplantation Methods 0.000 claims description 17
- 238000001574 biopsy Methods 0.000 claims description 10
- 230000008816 organ damage Effects 0.000 claims description 9
- 230000000451 tissue damage Effects 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 230000008439 repair process Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 230000000541 pulsatile effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 230000002572 peristaltic effect Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 abstract description 47
- 210000000663 muscle cell Anatomy 0.000 abstract description 14
- 239000002243 precursor Substances 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 8
- 239000007943 implant Substances 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 29
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 26
- 102100031013 Transgelin Human genes 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 19
- 210000002460 smooth muscle Anatomy 0.000 description 18
- 210000002027 skeletal muscle Anatomy 0.000 description 17
- 230000002062 proliferating effect Effects 0.000 description 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 14
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 210000002744 extracellular matrix Anatomy 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 229920012128 methyl methacrylate acrylonitrile butadiene styrene Polymers 0.000 description 11
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 108010082117 matrigel Proteins 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000012292 cell migration Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 206010030146 Oesophageal atresia Diseases 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 208000008929 esophageal atresia Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 238000001964 muscle biopsy Methods 0.000 description 6
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 6
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 6
- 238000000116 DAPI staining Methods 0.000 description 5
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000002747 omentum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003872 anastomosis Effects 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 102000006783 calponin Human genes 0.000 description 4
- 108010086826 calponin Proteins 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102100032970 Myogenin Human genes 0.000 description 3
- 108010056785 Myogenin Proteins 0.000 description 3
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 3
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000004876 tela submucosa Anatomy 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000145 Bacillolysin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 102000035092 Neutral proteases Human genes 0.000 description 2
- 108091005507 Neutral proteases Proteins 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 108010048992 Transcription Factor 4 Proteins 0.000 description 2
- 102100023489 Transcription factor 4 Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- -1 etc. Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 101150062988 dapF gene Proteins 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3882—Hollow organs, e.g. bladder, esophagus, urether, uterus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/22—Materials or treatment for tissue regeneration for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1515820.7 | 2015-09-07 | ||
| GBGB1515820.7A GB201515820D0 (en) | 2015-09-07 | 2015-09-07 | Tissue engineering |
| PCT/EP2016/071114 WO2017042232A1 (en) | 2015-09-07 | 2016-09-07 | Tissue engineering |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016319066A1 AU2016319066A1 (en) | 2018-04-19 |
| AU2016319066B2 true AU2016319066B2 (en) | 2020-05-14 |
Family
ID=54345872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016319066A Ceased AU2016319066B2 (en) | 2015-09-07 | 2016-09-07 | Tissue engineering |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10632229B2 (https=) |
| EP (1) | EP3347064B1 (https=) |
| JP (1) | JP6850287B2 (https=) |
| CN (1) | CN108348644B (https=) |
| AU (1) | AU2016319066B2 (https=) |
| CA (1) | CA2997576C (https=) |
| ES (1) | ES2803242T3 (https=) |
| GB (1) | GB201515820D0 (https=) |
| WO (1) | WO2017042232A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201708729D0 (en) * | 2017-06-01 | 2017-07-19 | Ucl Business Plc | Cryopreservation |
| WO2025087952A1 (en) | 2023-10-24 | 2025-05-01 | Universidad San Francisco De Quito Usfq | Bioreactor system |
| CN117653790B (zh) * | 2023-11-03 | 2024-10-25 | 柔脉医疗(深圳)有限公司 | 一种组织工程人工血管及其制备方法和应用 |
| WO2025155899A1 (en) * | 2024-01-19 | 2025-07-24 | The Trustees Of Columbia University In The City Of New York | Pump-free wearable 3d skin models and systems |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003092471A2 (en) * | 2002-05-02 | 2003-11-13 | Cook Biotech Incorporated | Cell-seeded extracellular matrix grafts |
| WO2003095631A1 (en) * | 2002-05-13 | 2003-11-20 | Fondazione Centro San Raffaele Del Monte Tabor | Method for establishing and expanding multipotent stem cells |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2138572A1 (en) * | 2008-06-26 | 2009-12-30 | t2cure GmbH | Mesoangioblast-like cell as well as methods and uses relating thereto |
-
2015
- 2015-09-07 GB GBGB1515820.7A patent/GB201515820D0/en not_active Ceased
-
2016
- 2016-09-07 CN CN201680064011.3A patent/CN108348644B/zh active Active
- 2016-09-07 AU AU2016319066A patent/AU2016319066B2/en not_active Ceased
- 2016-09-07 US US15/757,729 patent/US10632229B2/en active Active
- 2016-09-07 JP JP2018511613A patent/JP6850287B2/ja active Active
- 2016-09-07 CA CA2997576A patent/CA2997576C/en active Active
- 2016-09-07 ES ES16760757T patent/ES2803242T3/es active Active
- 2016-09-07 EP EP16760757.1A patent/EP3347064B1/en active Active
- 2016-09-07 WO PCT/EP2016/071114 patent/WO2017042232A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003092471A2 (en) * | 2002-05-02 | 2003-11-13 | Cook Biotech Incorporated | Cell-seeded extracellular matrix grafts |
| WO2003095631A1 (en) * | 2002-05-13 | 2003-11-20 | Fondazione Centro San Raffaele Del Monte Tabor | Method for establishing and expanding multipotent stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6850287B2 (ja) | 2021-03-31 |
| CA2997576A1 (en) | 2017-03-16 |
| CN108348644A (zh) | 2018-07-31 |
| GB201515820D0 (en) | 2015-10-21 |
| EP3347064B1 (en) | 2020-01-29 |
| WO2017042232A1 (en) | 2017-03-16 |
| JP2018532385A (ja) | 2018-11-08 |
| US20190038807A1 (en) | 2019-02-07 |
| EP3347064A1 (en) | 2018-07-18 |
| ES2803242T3 (es) | 2021-01-25 |
| CA2997576C (en) | 2023-07-04 |
| US10632229B2 (en) | 2020-04-28 |
| CN108348644B (zh) | 2021-06-25 |
| AU2016319066A1 (en) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6882391B2 (ja) | 肺臓の組織工学 | |
| Sakaguchi et al. | Construction of three-dimensional vascularized cardiac tissue with cell sheet engineering | |
| Campbell et al. | Development of tissue engineered vascular grafts | |
| JP6891010B2 (ja) | 実質組織からの細胞の移植方法 | |
| Bijonowski et al. | Bioreactor design for perfusion-based, highly vascularized organ regeneration | |
| Jia et al. | Regeneration of human-ear-shaped cartilage with acellular cartilage matrix-based biomimetic scaffolds | |
| US9592255B2 (en) | Scaffold-free three dimensional nerve fibroblast constructs | |
| KR20120023626A (ko) | 기관 및 조직의 탈세포화 및 재세포화 | |
| Gugatschka et al. | Regenerative medicine of the larynx. Where are we today? A review | |
| AU2016319066B2 (en) | Tissue engineering | |
| US20150344842A1 (en) | Method for production of decellularized biological material and the decellularized biological material prepared therefrom | |
| Wallis et al. | Feasibility study of a novel urinary bladder bioreactor | |
| CN108342356A (zh) | 一种软骨移植物及其构建方法 | |
| Gabouev et al. | In vitro construction of urinary bladder wall using porcine primary cells reseeded on acellularized bladder matrix and small intestinal submucosa | |
| Saxena | Esophagus tissue engineering: designing and crafting the components for the “hybrid construct” approach | |
| CN105963795A (zh) | 一种基于胶原制备组织工程表皮的方法 | |
| EP2755666B1 (de) | Verfahren zur herstellung eines biologischen gewebekonstrukts und verwendung spezifisch gewonnener autologer zellen und dessen medizinische verwendung | |
| TW201545779A (zh) | 製備去細胞化生物材料之方法及由其製備之去細胞化生物材料 | |
| Sabetkish et al. | Lung extracellular matrix as a platform for lung organ bioengineering: design and development of tissue engineered lung | |
| Fagiani | Development of novel bioreactors for oesophageal and parenchymatous organs tissue engineering | |
| Callese et al. | Decellularized Tissues for Bioengineering of Whole Organs | |
| CN121570650A (zh) | 一种含m2巨噬细胞的心肌类器官水凝胶体系及其制备方法和应用 | |
| Kiselevskiy et al. | Vascularized biocompatible synthetic tracheal matrix based on ultrafibrous polymeric material | |
| Inglin et al. | Bioengineering of Colo-Rectal Tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: UCL BUSINESS LTD Free format text: FORMER NAME(S): UCL BUSINESS PLC |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |